Acarbose-like drugs that inhibit the α-glucosidases present in the epithelium of the small intestine, have been shown to decrease postprandial hyperglycemia [22] and to improve impaired glucose metabolism without promoting insulin secretion in noninsulin dependent diabetes mellitus (NIDMM) patients [23]. Here, INS is linked to type 2 diabetes mellitus.